FLX Bio, Inc. Appoints Linda Kozick to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology.

Linda Kozick, FLX Bio Director

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177.

"We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio.

“FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." 

Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON).

Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University.

About FLX Bio

Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells.

Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.

Contact: 
Stephanie Ashe
650-245-0425
[email protected]